ASCO: Aceso’s Ivonesimab bests PD-1 inhibitor in lung cancer chemo combo, reducing risk of death by 34%.terrible pharma
A hotly debated lung cancer drug reduced the risk of death by 34% in a late-stage trial in China.cnbc
Akeso and Summit’s Ivonesimab extends survival in squamous cell lung cancerstatnews.com
The HARMONY-6 study, conducted by AKSAO in China, demonstrated a statistically significant overall survival benefit of ivonesimab plus chemotherapy compared with tislelizumab plus chemotherapy in the 1st treatment of patients with squamous NSCLC.yahoo finance
Lung cancer patients survived longer with China’s Akeso drugbloomberg.com
